Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2022 Filed Feb 15, 2022 21:38 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
GrantNon-qualified Stock Options · Derivative | 4,500 | $0.00 Strike: $276.26 | $0.00 |
DisclosureSEC source: 0001127602-22-005020 · form4.xml · derivative · entry 4 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2032-02-10 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:38 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
GrantRestricted Stock Unit · Derivative | 1,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005020 · form4.xml · derivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,011 Underlying: Common Stock · 1,270 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 18:49 UTC |
Schechter Adam HDirector · President & CEO
|
GrantNon-qualified Stock Options · Derivative | 28,100 | $0.00 Strike: $276.26 | $0.00 |
DisclosureSEC source: 0001127602-22-004969 · form4.xml · derivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,100 Underlying: Common Stock · 28,100 shares Expires 2032-02-10 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 18:49 UTC |
Schechter Adam HDirector · President & CEO
|
GrantRestricted Stock Unit · Derivative | 7,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004969 · form4.xml · derivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,031 Underlying: Common Stock · 7,970 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:40 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
GrantNon-qualified Stock Options · Derivative | 3,100 | $0.00 Strike: $276.26 | $0.00 |
DisclosureSEC source: 0001127602-22-005025 · form4.xml · derivative · entry 6 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,100 Underlying: Common Stock · 3,100 shares Expires 2032-02-10 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:40 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
GrantRestricted Stock Unit · Derivative | 870 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005025 · form4.xml · derivative · entry 5 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,546 Underlying: Common Stock · 870 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2019 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2019 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 17:37 UTC |
Williams R SandersDirector
|
GrantRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004962 · form4.xml · derivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 742 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 9, 2017. F3 · derivative.expiration_date: The Restricted Stock Units vest fully on February 12, 2019. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:37 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
GrantNon-qualified Stock Options · Derivative | 3,100 | $0.00 Strike: $276.26 | $0.00 |
DisclosureSEC source: 0001127602-22-005018 · form4.xml · derivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,100 Underlying: Common Stock · 3,100 shares Expires 2032-02-10 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:37 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
GrantRestricted Stock Unit · Derivative | 870 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005018 · form4.xml · derivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,928 Underlying: Common Stock · 870 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 18:48 UTC |
Seltz Judith CEVP, CHRO
|
GrantNon-qualified Stock Options · Derivative | 2,500 | $0.00 Strike: $276.26 | $0.00 |
DisclosureSEC source: 0001127602-22-004968 · form4.xml · derivative · entry 2 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2032-02-10 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 18:48 UTC |
Seltz Judith CEVP, CHRO
|
GrantRestricted Stock Unit · Derivative | 710 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004968 · form4.xml · derivative · entry 1 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,430 Underlying: Common Stock · 710 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 18:46 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
GrantNon-qualified Stock Options · Derivative | 1,900 | $0.00 Strike: $276.26 | $0.00 |
DisclosureSEC source: 0001127602-22-004967 · form4.xml · derivative · entry 2 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 Underlying: Common Stock · 1,900 shares Expires 2032-02-10 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 18:46 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
GrantRestricted Stock Unit · Derivative | 540 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004967 · form4.xml · derivative · entry 1 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,587 Underlying: Common Stock · 540 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 17:36 UTC |
Parham Richelle PDirector
|
GrantRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004960 · form4.xml · derivative · entry 1 Parham Richelle P · CIK 0001550078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 742 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2023. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 17:37 UTC |
Wengel Kathryn EDirector
|
GrantRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004961 · form4.xml · derivative · entry 1 Wengel Kathryn E · CIK 0001745955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,345 Underlying: Common Stock · 742 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 17:34 UTC |
BELINGARD JEAN-LUCDirector
|
GrantRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004958 · form4.xml · derivative · entry 1 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 742 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2023. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 17:34 UTC |
Davis Jeffrey A.Director
|
GrantRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004957 · form4.xml · derivative · entry 1 Davis Jeffrey A. · CIK 0001648477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 742 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2023. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 17:35 UTC |
ANDERSON KERRII BDirector
|
GrantRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004959 · form4.xml · derivative · entry 1 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 742 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2023. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 17:32 UTC |
Kong GarhengDirector
|
GrantRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004955 · form4.xml · derivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 742 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2023. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 17:33 UTC |
Gilliland Dwight GaryDirector
|
GrantRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004956 · form4.xml · derivative · entry 1 Gilliland Dwight Gary · CIK 0001603769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 742 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2023. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 17:31 UTC |
NEUPERT PETER MDirector
|
GrantRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004954 · form4.xml · derivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 742 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2023. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 16:08 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
SaleCommon Stock | 204 | $277.38 | $56,585.52 |
DisclosureSEC source: 0001127602-22-003647 · form4.xml · nonDerivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,605.4989 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 16:01 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
SaleCommon Stock | 218 | $277.38 | $60,468.84 |
DisclosureSEC source: 0001127602-22-003643 · form4.xml · nonDerivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,287.018 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:19 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionRestricted Stock Unit · Derivative | 373 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003652 · form4.xml · derivative · entry 3 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,676 Underlying: Common Stock · 373 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:19 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Tax withholdingCommon Stock | 109 | $277.48 | $30,245.32 |
DisclosureSEC source: 0001127602-22-003652 · form4.xml · nonDerivative · entry 2 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,643 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:19 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionCommon Stock | 373 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003652 · form4.xml · nonDerivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:18 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionRestricted Stock Unit · Derivative | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003651 · form4.xml · derivative · entry 3 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,095 Underlying: Common Stock · 560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:18 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Tax withholdingCommon Stock | 165 | $277.48 | $45,784.20 |
DisclosureSEC source: 0001127602-22-003651 · form4.xml · nonDerivative · entry 2 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,911.9106 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:18 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionCommon Stock | 560 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003651 · form4.xml · nonDerivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,076.9106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:13 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionRestricted Stock Unit · Derivative | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003649 · form4.xml · derivative · entry 3 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,771 Underlying: Common Stock · 560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:13 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Tax withholdingCommon Stock | 165 | $277.48 | $45,784.20 |
DisclosureSEC source: 0001127602-22-003649 · form4.xml · nonDerivative · entry 2 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,647 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:13 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionCommon Stock | 560 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003649 · form4.xml · nonDerivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:16 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionRestricted Stock Unit · Derivative | 970 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003650 · form4.xml · derivative · entry 3 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,476 Underlying: Common Stock · 970 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:16 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 286 | $277.48 | $79,359.28 |
DisclosureSEC source: 0001127602-22-003650 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,637 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:16 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionCommon Stock | 970 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003650 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:10 UTC |
Schechter Adam HDirector · President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003648 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,061 Underlying: Common Stock · 3,507 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:10 UTC |
Schechter Adam HDirector · President & CEO
|
Tax withholdingCommon Stock | 1,412 | $277.48 | $391,801.76 |
DisclosureSEC source: 0001127602-22-003648 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,474 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:10 UTC |
Schechter Adam HDirector · President & CEO
|
Exercise / conversionCommon Stock | 3,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003648 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:08 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionRestricted Stock Unit · Derivative | 560 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003647 · form4.xml · derivative · entry 4 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,741 Underlying: Common Stock · 560 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:08 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Tax withholdingCommon Stock | 152 | $277.48 | $42,176.96 |
DisclosureSEC source: 0001127602-22-003647 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,809.4989 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:08 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionCommon Stock | 560 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003647 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,961.4989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:03 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 267 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003645 · form4.xml · derivative · entry 3 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,047 Underlying: Common Stock · 267 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:03 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Tax withholdingCommon Stock | 83 | $277.48 | $23,030.84 |
DisclosureSEC source: 0001127602-22-003645 · form4.xml · nonDerivative · entry 2 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:03 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Exercise / conversionCommon Stock | 267 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003645 · form4.xml · nonDerivative · entry 1 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:06 UTC |
Seltz Judith CEVP, CHRO
|
Exercise / conversionRestricted Stock Unit · Derivative | 280 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003646 · form4.xml · derivative · entry 3 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720 Underlying: Common Stock · 280 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:06 UTC |
Seltz Judith CEVP, CHRO
|
Tax withholdingCommon Stock | 85 | $277.48 | $23,585.80 |
DisclosureSEC source: 0001127602-22-003646 · form4.xml · nonDerivative · entry 2 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,377.0452 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:06 UTC |
Seltz Judith CEVP, CHRO
|
Exercise / conversionCommon Stock | 280 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003646 · form4.xml · nonDerivative · entry 1 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,462.0452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:01 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003643 · form4.xml · derivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:01 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Tax withholdingCommon Stock | 82 | $277.48 | $22,753.36 |
DisclosureSEC source: 0001127602-22-003643 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,505.018 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:01 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003643 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,587.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.